Samsung C&T Corporation, Samsung Biologics, Samsung Bioepis and Samsung Venture Investment Corporation (collectively hereinafter referred to as “Samsung”) announced today an investment into Flagship Pioneering Fund VIII (“Fund VIII”) to help fuel breakthrough innovations in human health and sustainability. In addition to the strategic partnership that Flagship Pioneering (hereinafter referred

Overall Performance Revenue: KRW 10.796T, Operating Profit: KRW 712B – Year-over-Year (YoY) comparison: Revenue increased by KRW 557B (5.4%) from KRW 10.239T in Q1 2023,operating profit increased by KRW 71B (11.1%) from KRW 641B in Q1 2023 – Quarter-over-Quarter (QoQ) comparison: Revenue increased by KRW 696B (6.9%) from KRW 10.100B

– 2023 revenue KRW 41.896T, operating profit KRW 2.870T – Highest possible dividend payout under consistent dividend policy at KRW 2,550 per common stock and KRW 2,600 per preferred stock – Cancellation of treasury shares – 7,807,563 common shares (third of those currently held), 159,835 preferred shares (all of those

With another New Year upon us, it’s a reminder of how quickly the world’s advancing as we seek to seize opportunities and negotiate challenges. It’s also a time when many of us reflect on the past year. Looking back on 2023 recalls memories that made the year special for our

Overall Performance Revenue: KRW 10.971T, Operating Profit: KRW 830B – Year-over-Year (YoY) comparison: Revenue slightly decreased by KRW 285B (-2.5%) from KRW 11.256T in Q3 2022 Operating profit increased by KRW 33B (4.1%) from KRW 797B in Q3 2022 – Quarter-over-Quarter (QoQ) comparison: Revenue increased by KRW 385B (3.6%) from